Jakafi 10 MG tablet 60S
Ended Awarded
- Contract number
- SPE2DB25FYBGK
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $12,116
Award facts
- Contract value 100% obligated
- $12,115.65 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $12,115.65 by the Defense Logistics Agency on July 21, 2025, for the supply of Jakafi 10 mg tablets (60-count packages). The contract utilizes a firm fixed-price structure with no set-aside designation and carries an ultimate completion date of July 22, 2025. This delivery order is issued under DMS Pharmaceutical Group's existing single-award Indefinite Delivery Contract with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026, which authorizes the agency to procure a comprehensive range of pharmaceutical products supporting military health facilities worldwide.
As a critical supplier in the federal pharmaceutical supply chain, DMS Pharmaceutical Group has demonstrated consistent capability in delivering branded and generic prescription drugs, biologics, and medical consumables to Department of Defense healthcare sites. Jakafi (ruxolitinib) is a prescription medication used in the treatment of myelofibrosis and polycythemia vera, underscoring the company's role in providing specialized pharmaceutical products to support military medical operations. The expedited completion timeline reflects the routine nature of delivery orders issued under the existing IDC vehicle, enabling rapid fulfillment of pharmaceutical supply requirements across the Defense Department's healthcare network.
Quick answers
Who was awarded contract SPE2DB25FYBGK?
SPE2DB25FYBGK was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on July 21, 2025.
How much is contract SPE2DB25FYBGK worth?
The government has obligated $12,116 on SPE2DB25FYBGK.
Is contract SPE2DB25FYBGK an order under another contract?
Yes. SPE2DB25FYBGK is a delivery order under SPE2DB24D9313, an indefinite delivery contract.
Was contract SPE2DB25FYBGK competed?
The extent of competition for SPE2DB25FYBGK was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award